Member Info for chrishutch

This.

This is fab news and a solid indicator that we might see validation and big things soon

:-)

See their LinkedIn message

Interesting comments on Christopher kings post on LinkedIn

“After a little over a year in the development of my skills in the commercial team, I am happy to share that I’m starting a new position as Business Development Services Manager at Fusion Antibodies!“

Some of the comments and likes could be from clients… take a look

This is in line with what they desired as not solely focusing on one or two big ones, although would be welcomed.

This approach makes the company a lot safer as a more diverse range of work means not solely dependent on one source of income.

Not sure if you can see my question and answer on the investor hub? Once I have had a coffee I will see if I can copy paste.

But they appear to be winning lots of smaller contracts that aren’t rns’d as independently not material enough.

Been doing this long enough to know when something is a buy

Easy money

Should be a move higher at some point tomorrow so buying down here makes sense

For easy trade tomorrow

Revolutionising Antibody Development: Fusion's Commercial Strategies and Partnerships

In the second instalment of our "Unveiling Fusion Antibodies" series, CEO Adrian Kinkaid delves into Fusion's commercial model and the strategic partnerships that drive their success. Here's a snapshot of the key insights shared:

Understanding Fusion's Commercial Model: Adrian explains how Fusion supports organisations at various stages of development, providing a tailored approach to meet their unique needs. He outlines the step-by-step process Fusion uses to guide partners from early-stage research to advanced development.

Customer Base and Partnerships: Fusion collaborates with a diverse range of clients, including biotech companies, academic institutions, and pharmaceutical giants. Adrian discusses how these partnerships are commercialised, ensuring mutual growth and success.

Impact of Ongoing Developments: As Fusion continues to develop cutting-edge antibodies, the insights gained are continuously integrated into their processes. Adrian highlights how this ongoing learning enhances the company’s overall process and commercial value, positioning Fusion as a leader in the antibody development space.

Hopeful we see the one we are waiting for, before we get too old too enjoy the riches.

How is saying good morning, or sharing a link to someone else ramping?

Https://x.com/darrenukdaytra1/status/1826514945833341036?s=46

Let’s see what happens, I would think it should test that .052 area

Morning all,

No figures but still very positive, I would expect this to drift higher.

Hearing there will be an investor presentation announced soon.

Completely nt to buy